Subclassification of colorectal cancers can inform patient prognosis and response to treatment. Beyond these functions, a recent study demonstrates that molecular subty** can also play an important part in rational drug discovery, uncovering new indications for drugs previously thought ineffective.
This is a preview of subscription content, log in via an institution to check access.
References
Heinemann, V. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1065–1075 (2014).
Venook, A. P. et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) [abstract]. J. Clin. Oncol. 32 (Suppl. 5), LBA3 (2015).
Vecchione, L. et al. A vulnerability of a subset of colon cancers with potential clinical utility. Cell 165, 317–330 (2016).
Popovici, V. et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J. Clin. Oncol. 30, 1288–1295 (2012).
Douillard, J. Y. et al. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369, 1023–1034 (2013).
Hecht, J. R. et al. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat. Rev. 41, 653–659 (2015).
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
Corcoran, R. B. et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J. Clin. Oncol. 33, 4023–4031 (2015).
Kopetz, S. et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J. Clin. Oncol. 33, 4032–4038 (2015).
Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).
Acknowledgements
L.M.E. gratefully acknowledges the support of funding from The William C. Liedtke, Jr Chair in Cancer Research, and the US Department of Defense Grant CA140515.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Grothey, A., Ellis, L. Colorectal cancer: how to teach an old drug new tricks. Nat Rev Gastroenterol Hepatol 13, 384–385 (2016). https://doi.org/10.1038/nrgastro.2016.87
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2016.87
- Springer Nature Limited